Expression of TRIM47 and its significance in liver cancer base on bioinformatic test

doi:10.3877/cma.j.issn.2095-3232.2021.01.021

Abstract

Abstract:

Objective

To investigate the expression and clinical significance of tripartite motif-containing 47 (TRIM-47) gene in liver cancer.

Methods

The expression of TRIM47 mRNA and protein in liver cancer were analyzed by bioinformatics methods using UALCAN and HPA databases. The overall survival of liver cancer patients was analyzed by Kaplan-Meier survival database. The prognostic value of TRIM47 in liver cancer patients was evaluated. The frequency of TRIM47 gene mutation was analyzed by cBioPortal database. The effect of TRIM47 gene mutation on the overall survival of liver cancer patients was assessed. The liver cancer cell lines Hep3B and Huh-7 which stably expressed TRIM47 were constructed. The expression of TRIM47 mRNA in liver cancer cells was detected by qRT-PCR. The cell proliferation ability was detected by CCK-8 assay. The relative expression of TRIM47 mRNA and the proliferation ability of liver cancer cells were compared by rank-sum test or t test.

Results

UALCAN database analysis showed that the median relative expression of TRIM47 mRNA in liver cancer tissues was 18.95(10.79, 31.81), significantly higher than 7.09(5.76, 9.61) in normal liver tissues (P<0.05). HPA database analysis demonstrated that TRIM47 protein highly expressed in liver cancer tissues, whereas lowly expressed in normal liver tissues. UALCAN database revealed that with the up-regulation of TRIM47 expression in tumor tissues, the clinical stage and tumor grade became significantly worse (both P<0.05). Kaplan-Meier survival database analysis showed that the overall survival of liver cancer patients with low expression of TRIM47 was significantly longer (HR=1.59, 95%CI: 1.12-2.26; P<0.05). cBioPortal database analysis indicated that the mutation rate of TRIM47 gene in patients with liver cancer reached up to 14%, and significantly affected the overall survival (P=0.013 6). The mean relative expression levels of TRIM47 mRNA in Hep3B-TRIM47 and Huh-7-TRIM47 liver cancer cells were (4.87±0.14)×10^-3 and (2.47±0.47)×10^-3, significantly higher than (0.60±0.08)×10^-3 and (0.18±0.05)×10^-3 in the control group (t=26.560, 4.856; P<0.05). The proliferation ability of Hep3B-TRIM47 and Huh-7-TRIM47 cell lines was significantly enhanced.

Conclusions

TRIM47 can affect the clinical prognosis of patients with liver cancer by promoting the proliferation of liver cancer cells. TRIM47 may become a novel biomarker for predicting the prognosis of liver cancer patients.

Key words: Carcinoma, hepatocellular, Cell proliferation, TRIM47 gene, Computational biology

Juanhua Wu, Jiaojiao Gu, Yunyang Chen, Jiexiong Yu, Naile Kuang, Haochuan Huang. Expression of TRIM47 and its significance in liver cancer base on bioinformatic test[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(01): 98-103.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2021.01.021

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2021/V10/I01/98

Figures/Tables 4

References 19

[1]	Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[2]	Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis[J]. Cancer Biol Med, 2018, 15(2):124-136.
[3]	Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[4]	Dawkins J, Webster RM. The hepatocellular carcinoma market[J]. Nat Rev Drug Discov, 2019, 18(1):13-14.
[5]	Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis[J]. Trends Biochem Sci, 2017, 42(4):297-311.
[6]	Hatakeyama S. TRIM proteins and cancer[J]. Nat Rev Cancer, 2011, 11(11):792-804.
[7]	Fujimura T, Inoue S, Urano T, et al. Increased expression of tripartite motif (TRIM) 47 is a negative prognostic predictor in human prostate cancer[J]. Clin Genitourin Cancer, 2016, 14(4):298-303.
[8]	Li W, Zhang W, Deng W, et al. Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells[J]. Thorac Cancer, 2018, 9(11):1366-1375.
[9]	Liang Q, Tang C, Tang M, et al. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4[J].J Exp Clin Cancer Res, 2019, 38(1):159.
[10]	Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.
[11]	Asplund A, Edqvist PH, Schwenk JM, et al. Antibodies for profiling the human proteome-the human protein Atlas as a resource for cancer research[J]. Proteomics, 2012, 12(13):2067-2077.
[12]	Hou GX, Liu P, Yang J, et al. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter[J]. PLoS One, 2017, 12(3):e0174515.
[13]	Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment[J]. Nat Med, 2014, 20(11):1242-1253.
[14]	Micale L, Chaignat E, Fusco C, et al. The tripartite motif: structure and function[J]. Adv Exp Med Biol, 2012(770):11-25.
[15]	Cambiaghi V, Giuliani V, Lombardi S, et al. TRIM proteins in cancer[J]. Adv Exp Med Biol, 2012(770):77-91.
[16]	Zhou Z, Liu Y, Ma M, et al. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2017(96):98-103.
[17]	Huang XQ, Zhang XF, Xia JH, et al. Tripartite motif-containing3 (TRIM3) inhibits tumor growth and metastasis of liver cancer[J]. Chin J Cancer, 2017, 36(1):77.
[18]	Li L, Dong L, Qu X, et al. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion[J]. Int J Oncol, 2016, 48(4): 1639-1649.
[19]	Han Y, Tian H, Chen P, et al. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma[J]. Oncotarget, 2017, 8(14):22730-22740.

Please choose a citation manager

Content to export